Alaunos Therapeutics (TCRT) Interest Expenses (2011 - 2026)

Alaunos Therapeutics' (TCRT) quarterly Interest Expenses came in at $19000.0 in Q1 2026, up 58.33% on a QoQ basis from $12000.0 in Q3 2025.

Alaunos Therapeutics (TCRT) Interest Expenses (2011 - 2026) Analysis & Trends

Alaunos Therapeutics (TCRT) has 15 years of Interest Expenses data on file, last reported at $19000.0 in Q1 2026.

Quarterly Interest Expenses changed N/A year-over-year to $19000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19000.0 (down 86.62% YoY) and the FY2025 annual result came in at $213.6 million, changed N/A from the prior year.
Interest Expenses advanced to $19000.0 in Q1 2026, from $12000.0 in the prior quarter.
In the past five years, Interest Expenses ranged from a high of $69.0 million in Q2 2025 to a low of $12000.0 in Q3 2025.
A 4-year average of $7.4 million and a median of $770000.0 in 2022 frame the typical range for Interest Expenses.
The widest YoY moves for Interest Expenses: up 80.18% in 2022, down 85.79% in 2022.
Tracing TCRT's Interest Expenses over 4 years: stood at $900000.0 in 2022, then tumbled by 84.22% to $142000.0 in 2023, then tumbled by 91.55% to $12000.0 in 2025, then soared by 58.33% to $19000.0 in 2026.
The last three Interest Expenses figures came in at $19000.0 (Q1 2026), $12000.0 (Q3 2025), and $69.0 million (Q2 2025), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	11.00 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	39.74 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	82.05 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-4.89 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	20.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	93.62 Mn
10	Alaunos Therapeutics	4.28 Mn	4.16 Mn	-	-

Download Data